Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) is an Italian pharmaceutical company founded in Milan in 1926 by Giovanni Recordati. With its headquarters still based in Milan, the company engages in the discovery, development, manufacturing and commercialization of a broad portfolio of prescription drugs. Over its long history, Recordati has built expertise in both small-molecule and advanced pharmaceutical technologies, establishing itself as a specialist in targeted therapeutic areas.
The company’s operations are organized into two main business segments: Specialty Care and Established Pharmaceuticals. The Specialty Care division focuses on treatments for rare diseases, leveraging a growing pipeline and a network of partner companies to bring innovative therapies to market. The Established Pharmaceuticals segment markets branded prescription products across cardiology, urology, dermatology, gastroenterology and central nervous system disorders, supporting healthcare professionals with a range of well-known medicines, including treatments for hypertension, heart failure and digestive disorders.
Recordati serves a global market through an extensive network of subsidiaries and distribution partners spanning Europe, North America, Latin America, the Commonwealth of Independent States and parts of Asia. Its U.S. affiliate, Recordati Rare Diseases Inc., is dedicated to advancing therapies for orphan conditions, participating in clinical trials and collaborating with patient advocacy groups. The company maintains manufacturing sites in Italy, France and Mexico, ensuring compliance with international quality standards and timely supply to diverse markets.
Leadership of the Recordati Group remains in the hands of the Recordati family, with Giacomo Recordati serving as Chairman and Chief Executive Officer. Under his guidance, the company emphasizes a long-term strategic approach that balances research-driven innovation with disciplined commercial execution. Recordati continues to pursue selective acquisitions, strategic partnerships and internal R&D programs to strengthen its product pipeline and address evolving patient needs worldwide.
